Data from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial

MLA

Olivier Louis Chinot, et al. Data from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.c.6530345.

APA

Olivier Louis Chinot, Henry Dufour, Anne Barlier, Dominique Figarella-Branger, Karine Baumstarck, Mohamed Boucekine, Stéphane Honoré, Anita Cohen, Maryline Barrie, Emeline Tabouret, Stéphane Fuentes, Pierre-Hugues Roche, Michel Kalamarides, Catherine Roche, Didier Autran, Noémie Basset, Hadrien Peyrière, Matthieu Peyre, Ahmed Idbaih, … Thomas Graillon. (2023). Data from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. https://doi.org/10.1158/1078-0432.c.6530345

Chicago

Olivier Louis Chinot, Henry Dufour, Anne Barlier, Dominique Figarella-Branger, Karine Baumstarck, Mohamed Boucekine, Stéphane Honoré, et al. 2023. “Data from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial,” March. doi:10.1158/1078-0432.c.6530345.